Updated assay guides diagnosis of autoimmune liver disease: Anne Tebo, Ph.D. - Insights
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.
Maria Willrich, Ph.D., and Melissa Snyder, Ph.D., describe Mayo Clinic Laboratories' panel for proactive therapeutic drug monitoring of patients with inflammatory bowel disease. The panel expands options for clinicians assessing patients'...
MAG Antibody Testing [Test in Focus] - Insights
John Mills, Ph.D., explains Mayo Clinic Laboratories’ approach to MAG antibody testing. The ELISA-based assay uses higher reference ranges and human MAG antigen to detect MAG antibodies, which are associated with a rare, hard-to-treat...
We offer next-generation sequencing and comprehensive fluorescence in situ hybridization (FISH) panels, as well as extensive immunohistochemistry (IHC) offerings, to diagnose and monitor T-cell lymphoma.
Learn about our comprehensive MayoComplete solid tumor panel, which analyzes 515 genes for mutations, rearrangements, and amplifications.
Lung Cancer NGS Panel - Mayo Clinic Laboratories
Our targeted lung cancer panel assesses for mutations in eight genes, and rearrangements in four genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK.
Browse our menu of MayoComplete next-generation sequencing assays which are designed to identify a growing list of hematological cancers.
Find out how our streamlined approach to fluorescence in situ hybridization testing can simplify the ordering process and better meet patient needs.
Lipid assay improves cardiovascular risk prediction: Jeff Meeusen, Ph.D. - Insights
Jeff Meeusen, Ph.D., explains how Mayo Clinic Laboratories' new MI-Heart Ceramides assay helps guide the management of patients with mildly to moderately high cholesterol. The test measures levels of lipids beyond cholesterol that boost...
New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D. - Insights
Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test...